COPENHAGEN, November 22, 2016 /PRNewswire/ --
Acarix, a Swedish/Danish commercial stage medical device company specializing in non-invasive, non-radiation acoustic rule-out of Coronary Artery Disease (CAD), today announced the appointment of two highly experienced medical device industry executives, Dr. Werner Braun and Mr. Denis Gestin, in preparation for a listing of the company's shares on Nasdaq First North Premier in Stockholm. The appointments follow shortly after a major strategic investment from the Chinese company Puhua Jingxin Guzhou Health Management Partnership (Puhua Jingxin).
Dr. Werner Braun will become Chairman. Having received a PhD in plasma and laser physics from the Technical University in Munich for research at the Max Planck Institute for Plasma Physics, Dr Braun was instrumental in turning BIOTRONIK into Europe's largest privately-held medical device company in the cardiovascular arena. He is also Chairman at Miracor Medical Systems GmbH. New board member, Mr. Denis M. Gestin has been the President of International Division at St. Jude Medical Inc. since January 2008 and brings in-depth knowledge of cardiac device development and marketing.
CEO Søren Rysholt Christiansen commented: "We are delighted with the appointments of Dr. Braun and Mr. Gestin. Their in-depth knowledge of the cardiovascular device market will be invaluable as we head for the listing on Nasdaq First North Premier. The funds raised will be primarily used to execute our commercialization strategy and anticipated launch in Q2 2017. "
The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes. According to Christiansen the CADScor®System meets a major unmet need: "Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive and potentially harmful imaging and invasive coronary angiography, is inefficient. For example, a recent Danish study showed that more than 90% of patients presenting symptoms to their general practitioner do not have CAD. The Acarix CADScor®System provides an easy to use non-invasive tool able to rule out CAD with 96% negative predictive value. This also translates into a potential to reduce onward patient referrals by ~50%. - a win-win for patients, payers and physicians."
More at http://www.acarix.com